PARTNER 1 - Center for Research in Cancerology and Immunology Nantes/Angers (CRCINA)

8 teams from the CRCINA contribute to the LabEx IGO : team 1 (E. Scotet), team 2 (B. Dreno), team 3 (N. Labarrière), team 4 (M. Grégoire), team 5 (F. Altare), team 7 (Y. Delneste/P. Jeannin), team 9 (F. Vallette) and team 13 (F. Kraeber-Bodéré/M. Chérel).

The CRCINA (UMR1232 www.crcina.org, personnel n=168), in partnership with the clinical teams of Nantes and Angers University Hospital is an INSERM, CNRS and Nantes University joint research unit that combines fundamental, translational and clinical research. The research programs developed by the 8 teams implicated in the LabEx IGO aim at understanding the fundamental aspects of cellular immunity, whether on the innate side or the adaptive side, as well as the alterations of these responses in severe pathologies, namely certain solid tumors (ie, melanoma, colorectal cancer, mesothelioma, ovarian and brain cancers) and hematologic (ie, B cell malignancies) as well as infectious diseases induced by mycobacteria or viruses. Beyond basic information, these projects aim to propose innovative immunotherapeutic strategies, research programs that focus on the development of new radiopharmaceuticals and new methodologies for cancer therapy and the identification of targets involved in the tumor resistance of mature B cell-haematological diseases.


PARTNER 2 - Center for research in transplantation & immunology (CRTI)

All the teams from the CRTI (5) contribute to the LabEx IGO : team 1 (E. Chiffoleau/R. Josien), team 2 (I. Anegon/ C. Guillonneau), team 3 (G. Blancho), team 4 (S. Brouard/D. Laplaud) and team 5 (S. Limou/P-A. Gourraud)

The CRTI (UMR1064 www.crti.univ-nantes.fr, personnel n=180) is an INSERM and Nantes University joint research unit that gathers researchers and clinicians with various expertise in immunology, transplantation, autoimmunity, virology, regenerative medicine, genetic and bioinformatics and that is part of the Institute of Transplantation with the Department of Nephrology, Clinical Immunology, and Transplantation at CHU Nantes. The CRTI is organized in 5 teams that all contribute to the LabEx IGO. The main objectives of the CRTI research program are to improve treatments and patient monitoring in organ transplantation and immune-mediated inflammatory diseases (IMIDs) such as multiple sclerosis and inflammatory bowel diseases to prevent graft loss and immune-mediated tissue damages. The CRTI teams more specifically contribute to: 1. Deciphering and understanding the molecular, (epi)genomic and cellular mechanisms of immunoregulation and tolerance to identify new targetable pathways; 2. Developing new molecular and cellular immunotherapies (eg, TolDCs, polyclonal and CAR-Treg, Breg) for transplantation and IMIDs, among them the new EU H2020 programs RESHAPE and UPGRADE. These programs are done in collaboration with biotech companies that spun off the CRTI. (ie, Ose Immunotherapeutics, Xenothera, Aboleris Pharma, GoLiver) as well as others (TxCell) and using original preclinical animal models such as humanized rodents and primates; 3. Developing personalized medicine in organ transplantation and IMID through better understanding graft loss and tissue damage mechanism in human, biomarkers discovery and epidemiological studies (eg, the already funded profram RHU-KTDInnov); 4. Developing alternative to transplantation and tissue repair strategies using stem cells and regenerative medicine approaches with the stem cell facility of Nantes.


PARTNER 3 - Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC)

The MICMAC (UMR1236 micmac.univ-rennes1.fr, personnel n=45) is a single-team mixed structure associating the Rennes 1 University, INSERM and the Etablissement Français du Sang (EFS ; French Blood Agency).
Strongly relying on the University Hospital of Rennes (CHU), the team research project focuses on the physiopathology of B lymphomas based on translational and basic research approaches with specific interests for: i) Understanding the mechanisms (genetic/epigenetic/signaling pathways) of normal B-cell commitment toward plasma cell differentiation and its deregulation in lymphomagenesis; ii) Deciphering the bidirectional crosstalk between malignant B cells and their surrounding supportive niche including stromal cell, CD4pos T cell and myeloid cell subsets at the tissue (HD microscopy), cellular (functional assays, CYToF, flow cytometry) and molecular (genetic/epigenetic/single-cell) levels; iii) Identifying and validating prognostic and predictive biomarkers in lymphoma patient tumor and peripheral blood. For this reason, the UMR1236 unit is a member of the national Institut Carnot CALYM dedicated to the valorization of research in lymphomas (www.calym.org). In addition, the immunomonitoring lab, the SITI, has also developed a strong expertise in the monitoring of clinical trials based on the immunoregulatory properties of mesenchymal stromal cells (validated by the participation to the eCellFrance Infrastructure program, www.ecellfrance.com).


PARTNER 4 - B Lymphocytes and Autoimmunity (LBAI)

The LBAI (UMR 1227 www.univ-brest.fr/Immunologie, personnel n=43) is a single-team laboratory, associating Brest University and INSERM, that focuses its research projects on 4 major axes in the field of B lymphocytes in autoimmunity: (i) Mechanisms driving effector and regulatory functions in human B lymphocytes and alterations in systemic autoimmune diseases; (ii) Epigenetic problems and in particular those associated with methylation/hydroxymethylation defects of DNA during autoimmunity; (iii) Calcium signaling alterations in autoimmune B lymphocytes, focusing on one of the partners of the calcium signaling pathways, the STIM1 protein; (iv) New algorithmic approaches of OMIC data for the prediction of the efficacy of targeted therapies in patients with systemic autoimmune diseases. The UMR1227 is actually involved in 3 European projects dedicated to the stratification of patients with autoimmune diseases (IMI PRECISESADS, H2020 HarmonicSS and IMI2 NECESSITY).